Two weeks remain for pharmaceutical companies, regulators and other stakeholders to make their views known on controversial European Commission proposals to align compulsory licensing mechanisms and improve their efficiency across the EU member states.
The proposals, which are part of the EU’s efforts to be in a position to quickly develop and scale up the availability of critical medical products and technologies in health...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?